evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

480 questions · 484 findings · 52 reviews · Musculoskeletal

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 114 · 23.6%GRADE not reported 24 · 5%Very low 33 · 6.8%Low 145 · 30%Moderate 116 · 24%High 52 · 10.7%

Bisphosphonates vs placebo

Number of participants who experienced side effects related to use of bisphosphonates · Paget's disease of bone

Bisphosphonates showed no clear difference in number of participants who experienced side effects related to use… compared with placebo (low certainty).

1 finding from 1 review

Bisphosphonates vs placebo

Withdrawals due to adverse events · Paget's disease of bone

Bisphosphonates showed no clear difference in number of participants who withdrew due to adverse events compared with placebo (low certainty).

1 finding from 1 review

Certolizumab pegol 200 mg sc (with or without MTX) vs placebo (with or without MTX)

HAQ change from baseline Scale from: 0 to 3. · patients with rheumatoid arthritis in adults

Certolizumab pegol 200 mg sc (with or without MTX) showed no clear difference in HAQ change from baseline Scale from: 0 to 3. compared with placebo (with or without MTX) (moderate certainty).

1 finding from 1 review

Certolizumab pegol 200 mg sc (with or without MTX) vs placebo (with or without MTX)

DAS (low or remission) · patients with rheumatoid arthritis in adults

Certolizumab pegol 200 mg sc (with or without MTX) leads to higher proportion of patients achieving DAS < 2.6 (remission) compared with placebo (with or without MTX) (high certainty).

1 finding from 1 review

Certolizumab pegol 200 mg sc (with or without MTX) vs placebo (with or without MTX)

Radiological changes: Erosion Scores (ES) Scale from: 0 to 230. · patients with rheumatoid arthritis in adults

Certolizumab pegol 200 mg sc (with or without MTX) showed no clear difference in radiological changes: Erosion Scores (ES) Scale from: 0 to 230 compared with placebo (with or without MTX) (moderate certainty).

1 finding from 1 review

Celecoxib vs placebo

Number withdrawn due to adverse events · patients with osteoarthritis

Celecoxib showed no clear difference in number withdrawn due to adverse events compared with placebo (moderate certainty).

1 finding from 1 review

Celecoxib vs placebo

Number of participants experiencing any serious adverse events · patients with osteoarthritis

It is very uncertain whether celecoxib changes number experiencing any serious adverse events compared with placebo (very low certainty).

1 finding from 1 review

Celecoxib vs placebo

Number experiencing gastro‐intestinal events (perforation, ulcer, bleeds) · patients with osteoarthritis

It is very uncertain whether celecoxib changes number experiencing gastro‐intestinal events (perforation, ulcer,… compared with placebo (very low certainty).

1 finding from 1 review

Celecoxib vs placebo

Cardiovascular events (myocardial infarction, stroke) · patients with osteoarthritis

It is very uncertain whether celecoxib changes number experiencing cardiovascular events (myocardial infarction,… compared with placebo (very low certainty).

1 finding from 1 review

Celecoxib vs placebo

Clinical improvement: American College of Rheumatology 20% improvement criteria (ACR20) · patients with rheumatoid arthritis

Celecoxib probably leads to higher clinical improvement: American College of Rheumatology 20%… compared with placebo (moderate certainty).

1 finding from 1 review

Celecoxib vs placebo

Pain A 0 t o 100 visual or numerical scale, where 0 equals no pain at all and 100 is the worst pain imaginable · patients with rheumatoid arthritis
1 finding from 1 review

Celecoxib vs placebo

Cardiovascular events (myocardial infarction, stroke) · patients with rheumatoid arthritis
1 finding from 1 review

Celecoxib vs placebo

Incidence of gastroduodenal ulcers ≥ 3 mm · patients with rheumatoid arthritis

Celecoxib showed no clear difference in incidence of gastroduodenal ulcers ≥ 3 mm compared with placebo (low certainty).

1 finding from 1 review